GAC - I have thought about that some as well. After referring back chicagoest's post a couple of days ago it makes more sense. Medison's is going to assist them in going through the approval process in Israel. If they get approved there earlier than in some other countries then that could help Apabetalone leapfrog through other areas and gain credibility sooner than otherwise. As you mentioned it is a very small market in the grand scheme of things. Because of the regions small size this deal is not going to dramatically negatively affect continued negotiations. Whoever ends up buying this drug/company is still going to benefit if they negotiate in the revenues from these territories in the purchase anyway.

I like you was disappointed that this deal did not come with up front cash which honestly dumb founds me. I can get over it if there is reasonable justification but unfortunately RVX is not Big on details in their announcements. It would be nice to know if that double digit royalty was bigger than the double digit royalty that RVX has with Zenith for instance.

All IMO

tada